<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647360</url>
  </required_header>
  <id_info>
    <org_study_id>P13-699</org_study_id>
    <nct_id>NCT01647360</nct_id>
  </id_info>
  <brief_title>Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment</brief_title>
  <official_title>A Post- Marketing, Prospective,Multicenter, Observational Program: Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dydrogesterone is a retroprogesterone with a molecular structure similar to natural
      progesterone. As a C-21 steroid, it has a high affinity for progesterone receptors, a low
      antigonadotropic activity and antiestrogenic activity, but almost no estrogenic or androgenic
      activity. Dydrogesterone (DuphastonÂ©) is indicated for dysfunctional bleeding.

      In this study, women suffering from menorrhagia and who are treated with dydrogesterone will
      be observed for impact on QoL with the reduction in severity of bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EQ-5D Quality of Life questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>The EQ-5D assesses five dimensions of HRQOL: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension is measured on a three-point ordinal scale where a higher score corresponds to a worse health state (no limitation, some limitation, and greatest limitation in HRQOL). This will be evaluated at baseline and then at each follow up visit to see impact on quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pictorial Blood Assessment Chart (PBAC) score</measure>
    <time_frame>3 months</time_frame>
    <description>PBAC score of 100 or more corresponds with heavy menstrual bleeding. PBAC score will be assessed at each visit to see any improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Cycle Diary</measure>
    <time_frame>3 months</time_frame>
    <description>Change in the nature of menstruation will be taken into account based on the subjects' perception as recorded on the Menstrual Cycle Diary.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">210</enrollment>
  <condition>Menorrhagia</condition>
  <condition>Metrorrhagia</condition>
  <arm_group>
    <arm_group_label>Women with Heavy Menstrual Bleeding (HMB)</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women with heavy menstrual bleeding
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Females aged 18 to 45 years

          -  Subjects presenting with Heavy Menstrual Bleeding (HMB)

          -  Subjects with Pictorial Blood Assessment Chart (PBAC) score of 100 or more

          -  Subjects will be treated with dydrogesterone in accordance to the local label after
             enrollment in the trial

        Exclusion Criteria

          -  Subjects with structural or organic pathology as an underlying cause of HMB.

          -  Subjects with hypersensitivity to dydrogesterone

          -  Known or suspected progestogen dependent neoplasms

          -  Subjects with vaginal bleeding who have not been screened for organic or structural
             pathology as an underlying cause

          -  Subjects with acute or chronic liver disease

          -  Patients with depressive illness

          -  Subjects who are known to have rare hereditary problems of galactose intolerance, Lapp
             lactase deficiency or glucose-galactose malabsorption

          -  Nursing mothers

          -  Use of any other medication for uterine bleeding (including but not limited to
             progesterone, oral contraceptive pills, tranexamic acid etc)

          -  Use of Non-Steroidal Anti inflammatory Drugs (NSAIDs)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raeef Ahmed, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site reference ID/Investigator# 79836</name>
      <address>
        <city>Islamabad, Federal Capital</city>
        <zip>44000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77674</name>
      <address>
        <city>Karachi, Sindh</city>
        <zip>74000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77675</name>
      <address>
        <city>Karachi, Sindh</city>
        <zip>74000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator# 77676</name>
      <address>
        <city>Karachi, Sindh</city>
        <zip>74000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77677</name>
      <address>
        <city>Karachi, Sindh</city>
        <zip>74000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77680</name>
      <address>
        <city>Karachi, Sindh</city>
        <zip>74000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77681</name>
      <address>
        <city>Karachi, Sindh</city>
        <zip>74000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator # 77690</name>
      <address>
        <city>Lahore, Punjab</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77691</name>
      <address>
        <city>Lahore, Punjab</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator# 77694</name>
      <address>
        <city>Lahore, Punjab</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77695</name>
      <address>
        <city>Lahore, Punjab</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77696</name>
      <address>
        <city>Lahore, Punjab</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator# 77698</name>
      <address>
        <city>Lahore, Punjab</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77699</name>
      <address>
        <city>Lahore, Punjab</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77686</name>
      <address>
        <city>Multan, Punjab</city>
        <zip>60000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77687</name>
      <address>
        <city>Multan, Punjab</city>
        <zip>60000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77684</name>
      <address>
        <city>Multan, Punjab</city>
        <zip>6000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77689</name>
      <address>
        <city>Multan, Punjab</city>
        <zip>6000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator # 77693</name>
      <address>
        <city>Rawalpindi, Punjab</city>
        <zip>46000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator# 79834</name>
      <address>
        <city>Rawalpindi, Punjab</city>
        <zip>46000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2012</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metrorrhagia</keyword>
  <keyword>Menorrhagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

